Comprehensive medication guide to Dupixent including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Approximately 68% of commercially insured patients pay $0–$100 per month with the DUPIXENT MyWay Copay Card (up to $13,000/year coverage). Medicare Part D patients face a $2,100 annual out-of-pocket cap in 2026. Medicaid patients typically pay $1–$8 per fill. Prior authorization is required for nearly all plans.
Estimated Cash Pricing
$4,193 list price per carton (2 injections) as of January 2026; retail prices at specialty pharmacies typically range from $4,000–$5,500 per carton depending on the pharmacy. Discount cards like SingleCare may reduce the price to approximately $4,026 per carton.
Medfinder Findability Score
62/100
Summarize with AI
On this page
Dupixent (dupilumab) is a prescription biologic medication jointly developed and marketed by Sanofi and Regeneron Pharmaceuticals. It was first approved by the FDA on March 28, 2017, for moderate-to-severe atopic dermatitis (eczema) and has since become one of the most broadly approved biologics in medicine, with nine distinct FDA-approved indications as of 2026.
Dupixent is approved to treat: atopic dermatitis (ages 6 months+), asthma (ages 6+), chronic rhinosinusitis with nasal polyps (ages 12+), eosinophilic esophagitis (ages 1+, ≥15 kg), prurigo nodularis (adults), COPD (adults), chronic spontaneous urticaria (ages 6 months+), bullous pemphigoid (adults), and allergic fungal rhinosinusitis (ages 6+). All these conditions share a common inflammatory driver — the type 2 inflammatory pathway involving IL-4 and IL-13.
Dupixent is classified as an interleukin-4 receptor alpha (IL-4Rα) antagonist — a monoclonal antibody of the IgG4 subclass. It is not a steroid, not a JAK inhibitor, and not an immunosuppressant. It has no boxed warning, requires no laboratory monitoring, and has no known drug-to-drug interactions according to its prescribing information.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Dupixent works by blocking two inflammatory cytokines — interleukin-4 (IL-4) and interleukin-13 (IL-13) — that drive type 2 inflammation. These proteins are overactive in people with eczema, asthma, nasal polyps, and other conditions Dupixent treats. By binding to the IL-4Rα subunit (shared by both the IL-4 and IL-13 receptor complexes), dupilumab prevents both cytokines from triggering their downstream inflammatory cascade.
In the skin, this means reduced itch signaling, decreased skin barrier breakdown, and less inflammatory cell recruitment — leading to skin healing and clearing. In the airways, it reduces eosinophil accumulation and mucus overproduction, preventing asthma attacks. In the sinuses, polyps shrink and congestion improves. In the esophagus, eosinophilic inflammation decreases and swallowing improves.
Unlike traditional immunosuppressants, dupilumab targets only the type 2 inflammatory pathway — leaving other immune functions intact. This is why it has no increased risk of serious infections and does not require laboratory monitoring. Patients typically begin to see improvement within 2–4 weeks, with more significant results by weeks 12–16.
200 mg/1.14 mL — Prefilled pen
For asthma and weight-based pediatric dosing; also used in some adult COPD and CSU regimens
200 mg/1.14 mL — Prefilled syringe
Same dose as pen; for patients or caregivers who prefer syringe administration
300 mg/2 mL — Prefilled pen
Most common adult dose for atopic dermatitis; standard maintenance dose for most indications
300 mg/2 mL — Prefilled syringe
Same dose as pen; for patients who prefer or require syringe administration (age 6+ months)
Dupixent is not on the FDA's official drug shortage list in 2026. Sanofi and Regeneron continue manufacturing it without supply disruption. The drug is available at major specialty pharmacies including CVS Specialty, Walgreens Specialty, Accredo, and Optum Specialty. However, access remains challenging for many patients — not because of supply issues, but because of the complex system surrounding specialty biologics.
The primary barriers are: prior authorization requirements (nearly all commercial and Medicaid plans require PA), step therapy policies (patients must often try and fail on cheaper medications first), specialty pharmacy routing (must use the insurance plan's preferred specialty pharmacy), and high cost (approximately $4,193–$5,500 per carton without financial assistance).
Once prior authorization is approved, medfinder can help you quickly locate the specialty pharmacy in your area that carries Dupixent and can fill your prescription.
Dupixent is not a controlled substance and has no special DEA prescribing requirements. Any licensed physician, nurse practitioner, or physician assistant can technically write a Dupixent prescription. However, most insurance prior authorization requirements prefer or require that the prescription originate from or be co-managed by a specialist with expertise in the relevant condition.
Common prescribers by indication include:
Dermatologists — primary prescribers for atopic dermatitis, prurigo nodularis, and bullous pemphigoid
Allergists / Immunologists — prescribe for asthma, chronic spontaneous urticaria, and CRSwNP
Pulmonologists — prescribe for asthma and COPD
Otolaryngologists (ENTs) — prescribe for CRSwNP and AFRS
Gastroenterologists — prescribe for eosinophilic esophagitis (EoE)
Pediatricians (with relevant expertise) — for pediatric AD, asthma, and CSU in children
Nurse Practitioners (NPs) and Physician Assistants (PAs) — can prescribe, often in collaboration with specialists
Telehealth availability: The Dupixent manufacturer (Sanofi/Regeneron) offers a telehealth referral option via dupixent.com that connects patients with independent telehealth providers for initial evaluation. Telehealth is most practical for eczema and asthma evaluations; some indications (like EoE or CRSwNP) require in-person diagnostic testing before prescribing is appropriate.
No. Dupixent (dupilumab) is not a controlled substance and is not scheduled by the DEA. It is a prescription-only biologic medication, but it has no abuse potential and is not subject to the controlled substance regulations that govern medications like opioids, benzodiazepines, or stimulants.
As a prescription-only drug, Dupixent still requires a valid prescription from a licensed prescriber and must be dispensed through a licensed specialty pharmacy. While there are no federal refill restrictions (as there would be for a controlled substance), most insurance plans require annual or semi-annual prior authorization renewals.
In clinical trials for atopic dermatitis (the most studied indication), the most common side effects reported in at least 1% of patients were:
Injection site reactions (redness, pain, swelling, itching)
Conjunctivitis (pink eye) — the most frequently reported eye disorder
Blepharitis (eyelid inflammation)
Dry eye and eye pruritus (itchy eyes)
Keratitis (corneal inflammation — less common but more serious)
Eosinophilia (elevated eosinophil count)
Oral herpes (cold sores)
Nasopharyngitis (runny nose, sore throat)
Hypersensitivity reactions: anaphylaxis, AGEP, serum sickness, angioedema (seek emergency care)
Severe keratitis: can cause blindness if untreated — seek ophthalmology care immediately for eye pain, vision changes, or light sensitivity
Eosinophilic pneumonia or vasculitis (rare, particularly in asthma patients — contact doctor for worsening breathing, rash, or neurological symptoms)
Note: Dupixent does NOT have a boxed warning, does not suppress the immune system broadly, does not require lab monitoring, and has no known drug-to-drug interactions.
Know what you need? Skip the search.
Adbry (tralokinumab)
IL-13 selective biologic for moderate-to-severe eczema in patients 12 and older. Injected every 2 weeks; monthly dosing possible in responders. May have fewer eye side effects than Dupixent in some patients.
Ebglyss (lebrikizumab)
IL-13 selective biologic for moderate-to-severe eczema in patients 12 and older weighing at least 40 kg. Maintenance dosing can reduce to once every 4 weeks after response confirmed at 16 weeks.
Rinvoq (upadacitinib)
Oral once-daily JAK-1 inhibitor for moderate-to-severe eczema in adults and adolescents 12+. Head-to-head data shows higher skin clearance rates; carries a boxed warning for serious infections, blood clots, and cancer.
Nucala (mepolizumab)
IL-5 inhibitor biologic for eosinophilic asthma and CRSwNP in adults. Given monthly by subcutaneous injection. Specifically targets eosinophil-driven inflammation.
Prefer Dupixent? We can find it.
Live vaccines (all types)
majorAvoid live vaccines while on Dupixent. Complete all recommended live vaccinations before starting treatment. Non-live vaccines (flu shot, COVID-19, Shingrix, Tdap, pneumococcal) are safe.
Warfarin (Coumadin)
moderateDupixent may normalize CYP450 enzyme activity as inflammation resolves, potentially altering warfarin metabolism. Monitor INR when starting or stopping Dupixent.
Cyclosporine
moderateCYP450 normalization with Dupixent initiation may alter cyclosporine blood levels. Monitor drug concentrations upon starting or stopping Dupixent.
Other biologic immunomodulators (JAK inhibitors, other biologics)
majorShould not be combined with Dupixent. Concurrent use is generally contraindicated and insurance will not cover both simultaneously.
Oral corticosteroids
minorMay be used concurrently but should be tapered gradually — do not stop abruptly when starting Dupixent, particularly for asthma patients.
Dupixent (dupilumab) represents a major advance in the treatment of type 2 inflammatory diseases. With nine FDA-approved indications, a favorable safety profile, no boxed warning, and no required lab monitoring, it has become a first-line biologic choice for patients with moderate-to-severe eczema, eosinophilic asthma, nasal polyps, and several other conditions. More than 1 million patients worldwide are currently on Dupixent.
The primary challenge with Dupixent is not its effectiveness — it is access. Specialty pharmacy requirements, prior authorization, step therapy policies, and high cost create barriers that can delay or prevent patients from receiving the therapy they need. Savings programs like the DUPIXENT MyWay Copay Card (commercial insurance) and Patient Assistance Program (uninsured) can dramatically reduce or eliminate out-of-pocket costs for eligible patients.
If you have a valid prescription and approved prior authorization but are struggling to find a specialty pharmacy that can fill it, medfinder can help you locate the right pharmacy near you quickly.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini